Despite the differences at the cellular level, both CT45A1‐positive MSI‐H CRC patients (Fig. 6G) and CT45A1‐positive MSS CRC patients (Fig. S9C,D) had worse survival outcomes, suggesting the presence of distinct mechanisms underlying CT45A1‐driven cancer malignancy in these two CRC subtypes. This evidence concerns the gene CT45A1 and cancer.